Haleon plc

What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne, Panadol, Centrum, Advil, Voltaren, Otrivin, Parodontax, Polident and Poligrip, Aquafresh, and Emergen-C. Products are sold in more than 170 countries.

Is Haleon publicly traded?
Yes. Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on July 18, 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder.

Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara became CEO at the time of the demerger.

Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China. The company sells products in more than 170 countries.

How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums).

Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon. Both companies have been reducing their positions through secondary share placements. As of early 2026, both GSK and Pfizer have substantially reduced their stakes, each holding less than 10% of shares. The remaining shares are held by institutional investors and public shareholders.

What is Haleon's revenue?
Haleon reported FY2025 net revenue of approximately GBP 10.2 billion, with organic revenue growth of approximately 4%. The oral health category is the largest and fastest-growing segment, driven by Sensodyne. The company employs approximately 24,000 people and sells products in more than 170 countries.

Haleon's history as an independent company is brief, having been formed in July 2022, but its constituent brands have histories spanning decades and in some cases over a century.

The consumer healthcare division that became Haleon was assembled primarily through two major transactions. GSK (formerly GlaxoSmithKline) had built a consumer healthcare portfolio through decades of acquisitions, including the purchase of Beecham Group in 1989, which brought brands including Panadol and Aquafresh. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, with GSK holding a 68% stake and Pfizer holding 32%. This joint venture brought Pfizer's consumer health brands, including Advil, Centrum, Caltrate, and Emergen-C, into the combined portfolio.

The joint venture was named GSK Consumer Healthcare and operated as a standalone business unit within GSK from 2019. In 2021, GSK announced plans to demerge the consumer healthcare business as an independent publicly listed company, separating it from GSK's pharmaceutical and vaccines businesses. The rationale was that the consumer health business had different growth characteristics, capital requirements, and investor profiles from the prescription pharmaceutical business.

Haleon plc was incorporated and listed on the London Stock Exchange on July 18, 2022, in what was the largest London Stock Exchange listing in over a decade. GSK distributed shares in Haleon to its own shareholders, and Pfizer retained a stake in the newly independent company. Brian McNamara was appointed as CEO of Haleon at the time of the demerger, having previously served as CEO of GSK Consumer Healthcare.

Following the demerger, Haleon focused on establishing itself as an independent company with its own management team, governance structure, and strategic priorities. The company's initial strategic framework focused on organic revenue growth through innovation, geographic expansion, and increased investment in its leading brands.

In 2023 and 2024, Haleon delivered organic revenue growth within its medium-term guidance range of 4% to 6%, driven by strong performances from Sensodyne, Centrum, and Voltaren. The company also began returning capital to shareholders through share buyback programs. GSK and Pfizer both gradually reduced their remaining stakes in Haleon through secondary share placements during 2023 and 2024.

For the full year 2025, Haleon reported organic revenue growth of approximately 4%, with net revenues of approximately GBP 10.2 billion. Sensodyne delivered strong growth in India and China, Centrum Daily Kits performed well in China, and Voltaren continued its global expansion. The oral health segment was the strongest performer, delivering double-digit growth driven by the rollout of Sensodyne's Clinical Platform innovation.

Haleon publishes an annual sustainability report and has made commitments across environmental, social, and governance dimensions. The company has set targets to reduce Scope 1 and Scope 2 carbon emissions by 2030 and to achieve net zero across its operations by 2040. These are self-reported targets aligned with the Science Based Targets initiative.

On environmental sustainability, Haleon has invested in sustainable packaging, including recyclable toothpaste tubes through a partnership with Colgate-Palmolive and others in the Tomra-led recycling initiative. The company has reduced plastic use in product packaging and set targets for increasing the use of recycled materials.

On access to healthcare, Haleon operates programs to expand access to consumer health products in underserved markets. The company partners with NGOs and governments to provide health education and products in low-income communities. Haleon's oral health education programs, tied to the Sensodyne and Aquafresh brands, operate in multiple countries.

Haleon is not a Certified B Corporation. Its sustainability commitments are self-reported in its annual ESG report, which follows the Global Reporting Initiative (GRI) standards.

Haleon and its brands have received recognition for innovation, brand strength, and sustainability:

• Brand strength: Sensodyne ranked as the world's leading sensitivity toothpaste brand by market share, recognized in multiple industry awards
• Innovation: Centrum Daily Kits recognized for innovative product format in the Chinese market
• Sustainability: Recognition for sustainable packaging initiatives, including recyclable toothpaste tube development
• Corporate governance: Haleon's board structure and governance practices recognized following the 2022 demerger, consistent with UK premium listing requirements
• Workplace: Recognition as a top employer in the consumer healthcare sector in multiple markets

Haleon has faced several notable issues:

Zantac litigation: Haleon inherited certain legal liabilities from its predecessor companies at the time of the demerger from GSK. The most significant relates to Zantac (ranitidine), a heartburn medication that was sold under various brands including Zantac by GSK's consumer healthcare division before being withdrawn from the market in 2020 following concerns about the presence of NDMA, a potential carcinogen. Haleon has faced litigation related to Zantac claims. GSK and Pfizer have indemnified Haleon for a portion of these liabilities under the terms of the demerger agreement. The litigation is ongoing, with cases consolidated in multi-district litigation in the United States. Haleon has set aside provisions for potential liabilities.

Regulatory oversight: Haleon's products are subject to regulatory oversight by health authorities in each market where they are sold, including the U.S. Food and Drug Administration, the European Medicines Agency, and equivalent bodies in other countries. The company's consumer health products must comply with labeling, safety, and efficacy requirements in each jurisdiction. Changes in regulatory classification of over-the-counter products could affect revenue.

Private-label competition: Haleon faces ongoing competitive pressure from private-label (store brand) products in pharmacy and supermarket channels. Private-label products are typically priced below branded alternatives and have improved in quality over time. This is an ongoing market dynamic rather than a controversy, but it represents a persistent challenge to Haleon's premium pricing strategy.

GSK and Pfizer share overhang: The gradual reduction of GSK and Pfizer's remaining stakes in Haleon through secondary share placements has created a share price overhang, as large secondary placements can depress the market price. This is a financial market dynamic rather than a controversy, but it has been a factor in Haleon's share price performance since the demerger. As of early 2026, both companies have substantially reduced their stakes, reducing this overhang.